NeoPharm CO., LTD.

KOSDAQ:A092730 Stock Report

Market Cap: ₩185.6b

NeoPharm Past Earnings Performance

Past criteria checks 2/6

NeoPharm has been growing earnings at an average annual rate of 3.7%, while the Personal Products industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 5.3% per year. NeoPharm's return on equity is 13.1%, and it has net margins of 19.9%.

Key information

3.7%

Earnings growth rate

3.1%

EPS growth rate

Personal Products Industry Growth3.8%
Revenue growth rate5.3%
Return on equity13.1%
Net Margin19.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings

Nov 20
We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings

NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Mar 25
NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Recent updates

We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings

Nov 20
We Think That There Are Some Issues For NeoPharm (KOSDAQ:092730) Beyond Its Promising Earnings

The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence

Nov 13
The Returns On Capital At NeoPharm (KOSDAQ:092730) Don't Inspire Confidence

NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors

Sep 13
NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors

NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends

Aug 07
NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends

NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Jun 13
NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected

Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

Apr 24
Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price

NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Mar 25
NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Mar 28
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Mar 15
What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

Mar 02
How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?

We're Watching These Trends At NeoPharm (KOSDAQ:092730)

Feb 18
We're Watching These Trends At NeoPharm (KOSDAQ:092730)

We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

Feb 08
We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings

NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

Jan 26
NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock

An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Jan 15
An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued

Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

Jan 04
Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?

NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Dec 24
NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Dec 15
What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?

Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Dec 04
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?

Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Nov 23
Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?

Revenue & Expenses Breakdown

How NeoPharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A092730 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24112,20022,33438,3693,035
30 Jun 24107,85822,92937,4902,838
31 Mar 24101,73522,51637,3052,690
31 Dec 2397,10523,21336,2762,647
30 Sep 2392,27120,73334,9242,777
30 Jun 2389,29219,78134,1422,739
31 Mar 2386,27218,91233,0872,805
31 Dec 2285,03317,02732,9842,854
30 Sep 2286,80518,24534,6852,898
30 Jun 2287,42417,37035,7903,043
31 Mar 2287,32116,90535,5872,945
31 Dec 2187,93117,71336,0222,935
30 Sep 2186,80218,20735,0872,764
30 Jun 2185,27518,05934,1072,658
31 Mar 2185,28718,47434,5092,880
31 Dec 2081,62518,13132,9912,802
30 Sep 2081,41318,73434,0942,824
30 Jun 2082,61819,93533,9052,768
31 Mar 2082,68019,90133,4072,602
31 Dec 1983,24019,24533,9582,518
30 Sep 1979,61118,00231,0382,550
30 Jun 1974,86316,67529,5622,659
31 Mar 1969,50015,79527,6542,616
31 Dec 1866,27515,37026,2752,576
30 Sep 1863,14313,68226,5922,616
30 Jun 1860,23613,10525,4952,355
31 Mar 1857,17512,51424,5772,257
31 Dec 1753,63411,55923,6262,098
30 Sep 1749,7659,81423,0972,105
30 Jun 1746,7399,36521,3722,068
31 Mar 1743,1648,09619,7262,184
31 Dec 1642,3697,74219,6782,183
30 Sep 1643,0975,95519,9022,206
30 Jun 1641,9995,41919,8312,209
31 Dec 1535,9653,40717,9981,973

Quality Earnings: A092730 has a high level of non-cash earnings.

Growing Profit Margin: A092730's current net profit margins (19.9%) are lower than last year (22.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A092730's earnings have grown by 3.7% per year over the past 5 years.

Accelerating Growth: A092730's earnings growth over the past year (7.7%) exceeds its 5-year average (3.7% per year).

Earnings vs Industry: A092730 earnings growth over the past year (7.7%) did not outperform the Personal Products industry 62.4%.

Return on Equity

High ROE: A092730's Return on Equity (13.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 20:42
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NeoPharm CO., LTD. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo Min KangCape Investment & Securities Co., Ltd.
Jiseon AnDAOL Investment & Securities Co., Ltd.
Hyeon Jin ParkDB Financial Investment Co. Ltd.